These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 29710336)

  • 1. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
    Bergmark BA; Udell JA; Morrow DA; Cannon CP; Steen DL; Jarolim P; Budaj A; Hamm C; Guo J; Im K; Kuder JF; Braunwald E; Sabatine MS; O'Donoghue ML
    JAMA Cardiol; 2018 Jun; 3(6):473-480. PubMed ID: 29710336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.
    Fanola CL; Morrow DA; Cannon CP; Jarolim P; Lukas MA; Bode C; Hochman JS; Goodrich EL; Braunwald E; O'Donoghue ML
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome.
    Correa S; Morrow DA; Braunwald E; Davies RY; Goodrich EL; Murphy SA; Cannon CP; O'Donoghue ML
    J Am Heart Assoc; 2018 Oct; 7(20):e009077. PubMed ID: 30371283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
    O'Donoghue ML; Braunwald E; White HD; Lukas MA; Tarka E; Steg PG; Hochman JS; Bode C; Maggioni AP; Im K; Shannon JB; Davies RY; Murphy SA; Crugnale SE; Wiviott SD; Bonaca MP; Watson DF; Weaver WD; Serruys PW; Cannon CP; ; Steen DL
    JAMA; 2014 Sep; 312(10):1006-15. PubMed ID: 25173516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.
    Mani P; Puri R; Schwartz GG; Nissen SE; Shao M; Kastelein JJP; Menon V; Lincoff AM; Nicholls SJ
    JAMA Cardiol; 2019 Apr; 4(4):314-320. PubMed ID: 30840024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.
    Bergmark BA; Udell JA; Morrow DA; Jarolim P; Kuder JF; Solomon SD; Pfeffer MA; Braunwald E; Sabatine MS
    Eur J Heart Fail; 2019 Apr; 21(4):462-470. PubMed ID: 30773798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.
    Eisen A; Cannon CP; Braunwald E; Steen DL; Zhou J; Goodrich EL; Im K; Dalby AJ; Spinar J; Daga S; Lukas MA; O'Donoghue ML
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28077384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
    Held C; White HD; Stewart RAH; Budaj A; Cannon CP; Hochman JS; Koenig W; Siegbahn A; Steg PG; Soffer J; Weaver WD; Östlund O; Wallentin L;
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Held C; White HD; Stewart RAH; Davies R; Sampson S; Chiswell K; Silverstein A; Lopes RD; Heldestad U; Budaj A; Mahaffey KW; Wallentin L;
    Am Heart J; 2019 Feb; 208():65-73. PubMed ID: 30572273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease.
    Stewart RAH; Hagström E; Held C; Wang TKM; Armstrong PW; Aylward PE; Cannon CP; Koenig W; López-Sendón JL; Mohler ER; Hadziosmanovic N; Krug-Gourley S; Ramos Corrales MA; Siddique S; Steg PG; White HD; Wallentin L;
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.
    Schwartz GG; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Nicholls SJ; Olsson AG; Shah PK; Tardif JC; Kittelson J
    JAMA Cardiol; 2018 Feb; 3(2):164-168. PubMed ID: 29071331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darapladib for preventing ischemic events in stable coronary heart disease.
    ; White HD; Held C; Stewart R; Tarka E; Brown R; Davies RY; Budaj A; Harrington RA; Steg PG; Ardissino D; Armstrong PW; Avezum A; Aylward PE; Bryce A; Chen H; Chen MF; Corbalan R; Dalby AJ; Danchin N; De Winter RJ; Denchev S; Diaz R; Elisaf M; Flather MD; Goudev AR; Granger CB; Grinfeld L; Hochman JS; Husted S; Kim HS; Koenig W; Linhart A; Lonn E; López-Sendón J; Manolis AJ; Mohler ER; Nicolau JC; Pais P; Parkhomenko A; Pedersen TR; Pella D; Ramos-Corrales MA; Ruda M; Sereg M; Siddique S; Sinnaeve P; Smith P; Sritara P; Swart HP; Sy RG; Teramoto T; Tse HF; Watson D; Weaver WD; Weiss R; Viigimaa M; Vinereanu D; Zhu J; Cannon CP; Wallentin L
    N Engl J Med; 2014 May; 370(18):1702-11. PubMed ID: 24678955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).
    Vaduganathan M; White WB; Charytan DM; Morrow DA; Liu Y; Zannad F; Cannon CP; Bakris GL;
    Am J Cardiol; 2019 Feb; 123(3):382-391. PubMed ID: 30477800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.
    O'Donoghue ML; Braunwald E; White HD; Serruys P; Steg PG; Hochman J; Maggioni AP; Bode C; Weaver D; Johnson JL; Cicconetti G; Lukas MA; Tarka E; Cannon CP
    Am Heart J; 2011 Oct; 162(4):613-619.e1. PubMed ID: 21982651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.
    Lindholm D; Lindbäck J; Armstrong PW; Budaj A; Cannon CP; Granger CB; Hagström E; Held C; Koenig W; Östlund O; Stewart RAH; Soffer J; White HD; de Winter RJ; Steg PG; Siegbahn A; Kleber ME; Dressel A; Grammer TB; März W; Wallentin L
    J Am Coll Cardiol; 2017 Aug; 70(7):813-826. PubMed ID: 28797349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).
    O'Malley RG; Bonaca MP; Scirica BM; Murphy SA; Jarolim P; Sabatine MS; Braunwald E; Morrow DA
    J Am Coll Cardiol; 2014 Apr; 63(16):1644-53. PubMed ID: 24530676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
    Verma S; Bain SC; Buse JB; Idorn T; Rasmussen S; Ørsted DD; Nauck MA
    JAMA Cardiol; 2019 Dec; 4(12):1214-1220. PubMed ID: 31721979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study).
    Schopfer DW; Ku IA; Regan M; Whooley MA
    Am Heart J; 2014 Feb; 167(2):186-192.e1. PubMed ID: 24439979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome.
    Batra G; Ghukasyan Lakic T; Lindbäck J; Held C; White HD; Stewart RAH; Koenig W; Cannon CP; Budaj A; Hagström E; Siegbahn A; Wallentin L;
    JAMA Cardiol; 2021 Dec; 6(12):1440-1445. PubMed ID: 34431970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
    O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.